Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Reducing Tobacco Related Health Disparities

Not Applicable

Completed

Conditions: Smoking Cessation
Smoking

Interventions: Behavioral: Standard Treatment (ST)
Behavioral: Telephone Counseling
Behavioral: Quitline
Behavioral: Nicotine Replacement Therapy (NRT)

First Posted Date: 2009-09-25

Last Posted Date: 2016-10-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 639

Registration Number: NCT00984724

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Celecoxib as a Chemopreventive Agent in Current and Former Smokers

Phase 3

Completed

Conditions: Smoking
Prevention

Interventions: Drug: Celecoxib
Drug: Placebo

First Posted Date: 2009-09-22

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 219

Registration Number: NCT00981201

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver

Phase 1

Completed

Conditions: Liver Cancer
Advanced Cancer

Interventions: Drug: Irinotecan
Drug: Bevacizumab
Drug: Oxaliplatin
Drug: Cetuximab

First Posted Date: 2009-09-21

Last Posted Date: 2015-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 115

Registration Number: NCT00980239

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Infusion of Expanded Cord Blood T Cells

Phase 1

Withdrawn

Conditions: Stem Cell Transplantation
Leukemia
Lymphoma
Pediatric Disorders

Interventions: Drug: Melphalan
Radiation: Total Body Irradiation (TBI)
Drug: Thiotepa
Drug: Fludarabine
Drug: Etoposide
Drug: Rituximab
Drug: Anti-thymocyte globulin (ATG)
Drug: Mycophenolate Mofetil (MMF)
Drug: Tacrolimus
Procedure: Cord Blood Infusion
Drug: G-CSF
Procedure: Ex vivo expanded T cell Infusion

First Posted Date: 2009-09-04

Last Posted Date: 2012-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00972101

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: Temozolomide
Drug: Abraxane
Drug: Cisplatin
Biological: Interleukin-2
Biological: Interferon alpha 2b

First Posted Date: 2009-09-03

Last Posted Date: 2013-01-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00970996

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Discount Generic Prescription Study

Completed

Conditions: Poverty
Low-Income Population

Interventions: Behavioral: Survey
Behavioral: Focus Group

First Posted Date: 2009-09-03

Last Posted Date: 2012-04-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 574

Registration Number: NCT00971022

Locations: 🇺🇸
Independence Heights Community Health Center, Houston, Texas, United States
🇺🇸
Second Mile Mission Center, Houston, Texas, United States
🇺🇸
HOPE Clinic, Houston, Texas, United States

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Phase 1

Completed

Conditions: B-cell Lymphoma
Lymphoma

Interventions: Procedure: Leukapheresis
Procedure: Stem Cell Transplant
Procedure: CD19-specific T Cell Infusion
Drug: Carmustine
Drug: IL-2
Drug: Etoposide
Drug: Melphalan
Drug: Cytarabine

First Posted Date: 2009-08-31

Last Posted Date: 2023-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT00968760

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Study for Leukemia Patients With Life-Threatening Infections

Phase 3

Completed

Conditions: Leukemia

Interventions: Procedure: White Blood Cell Transfusion

First Posted Date: 2009-08-31

Last Posted Date: 2013-11-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 178

Registration Number: NCT00968838

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

C-VISA BikDD: Liposome in Advanced Pancreatic Cancer

Phase 1

Withdrawn

Conditions: Pancreatic Cancer

Interventions: Genetic: BikDD Nanoparticle

First Posted Date: 2009-08-31

Last Posted Date: 2019-04-11

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00968604

Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders

Phase 1

Withdrawn

Conditions: Leukemia
Lymphoproliferative Disorders

Interventions: Drug: Phenethyl Isothiocyanate (PEITC)

First Posted Date: 2009-08-31

Last Posted Date: 2013-04-15

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00968461

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy